Loading clinical trials...
Loading clinical trials...
The aim of the study is to compare the effectiveness of rifaximin versus norfloxacin for secondary prevention of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites.
This study will be carried out on 100 patients with liver cirrhosis and ascites who will be enrolled from Tanta University, Tropical Medicine Department in the period between January 2014 to 6 months. The selected patients will be randomly assigned to receive 400 mg of norfloxacin daily or 1200 mg of rifaximin daily and will be classified into two groups : Group 1 : 50 patients will be treated with 1200 mg of rifaximin daily. Group 2 : 50 patients will be treated with 400 mg of norfloxacin daily.
Age
18 - 75 years
Sex
ALL
Healthy Volunteers
No
Tanta university hospital
Tanta, Egypt
Start Date
January 1, 2014
Primary Completion Date
December 1, 2023
Completion Date
December 1, 2023
Last Updated
January 9, 2018
100
ESTIMATED participants
Rifaximin
DRUG
Norfloxacin
DRUG
Lead Sponsor
Sherief Abd-Elsalam
Collaborators
NCT06169592
NCT07275554
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions